Stock Watch: Biopharma Caught In US Government Anti-Bundling Drive
Two Big Issues, One Common Factor
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.
